At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 150 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 130
- Started
- 2025-02-12
- Last checked
- 2026-04
Plain English Summary
What is this study?
- • Testing a new treatment for heart failure with preserved ejection fraction (hfpef)
- • Clinical study - 130 participants
- • In this study the investigators are aiming to recruit 130 patients with heart failure with preserved ejection fraction who are obese and non-obese to undergo CT and MRI scans, as well as some other investigations including blood tests, to help investigate if having more fat around the heart leads to worse heart function in this condition
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with heart failure with preserved ejection fraction (hfpef)
Where?
- • Leicester - Glenfield Hospital, University Hospitals of Leicester
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
In this study the investigators are aiming to recruit 130 patients with heart failure with preserved ejection fraction who are obese and non-obese to undergo CT and MRI scans, as well as some other investigations including blood tests, to help investigate if having more fat around the heart leads to worse heart function in this condition. This may lead to the development of new treatments aimed at lowering fat levels around the heart and in the rest of the body, specifically to treat HFpEF.
More detail
Dysregulated adipose tissue, in particular epicardial adipose tissue (EAT; fat around the heart) may be central to the pathogenesis of obesity related HFpEF. Existing studies have been limited by selection bias (only including obese cohorts), limited cardiac structural and functional assessment (primarily using echocardiography) and lack of corroborating biological data to imply causality. Pilot data demonstrate important associations between EAT with concentric LV remodelling in cohorts at high risk of HFpEF. Further exploration of the role of EAT and other ectopic fat depots in patients with HFpEF with and without obesity, will provide novel insights into mechanisms by which adiposity drives development of HFpEF. In this single centre, prospective, case-control study the investigators will recruit participants with HFpEF with and without obesity (total N=130) and utilise multimodality imaging to comprehensively characterise the role of excess adiposity and ectopic fat, specifically EAT, to cardiac dysfunction in HFpEF.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
Biomarkers mentioned
What the study is looking for
- ✓Participant is willing and able to give agreement to take part for participation in the study.
- ✓Aged ≥18 years old
- ✓Diagnosed with HFpEF by an experienced cardiologist or signs and symptoms of heart failure with a HFA-PEFF score ≥5
- ✓Able to understand written English
Who cannot take part
- ✗LV ejection fraction \<45%
- ✗Recovered ejection fraction (previous ejection fraction \<40%) unless reduced ejection fraction was in context of...
- ✗Severe primary valvular heart disease
- ✗HFpEF due to infiltrative cardiomyopathy (heart amyloidosis or sarcoidosis), genetic hypertrophic cardiomyopathy,...
- ✗Known heritable, idiopathic or drug-induced lung arterial hypertension
See the full criteria
Where Is This Study? (1 UK site)
Glenfield Hospital, University Hospitals of Leicester
Leicester LE3 9QP, United Kingdom
How to Get in Touch
Gaurav S Gulsin, MBChB(Hons)
Sponsor contactCONTACT
Sarah L Ayton, MBBS
Sponsor contactCONTACT